ScreenerHero

CLYM Climb Bio Inc

NAS · US · Healthcare · Biotechnology · climbbio.com
10.71USD+0.28%Mkt Cap: 615.14M $P/E: —

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap615.14M USD
Enterprise Value431.61M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.85M USD
Revenue/Share—
Last Price10.71 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.65
PEG—
EV/EBITDA-6.68
EV/Revenue—
P/S—
P/B2.56
EPS (TTM)-0.79
EPS (Forward)-1.00
52W Range
1.54055% of range18.14
52W High18.14 USD
52W Low1.540 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.30%
ROA-35.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M USD
CapEx (TTM)186.00K USD
FCF Margin—
FCF Yield-5.53%
Net Debt-181.81M USD
Net Debt/EBITDA2.81
Balance Sheet
Debt/Equity0.00
Current Ratio31.45
Quick Ratio30.86
Book Value/Sh4.17 USD
Cash/Share3.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.57 USD
Upside (mean)+157.4%
Target Range18.00 USD – 40.00 USD
18.00+157.4% to mean40.00
# Analysts14
Ownership
Shares Out.57.44M
Float38.74M
Insiders0.18%
Institutions105.55%
Short Interest
Short Ratio5.4d
Short % Float20.89%
Short % Out.14.81%
Shares Short8.51M
Short (prev mo.)7.56M
Technical
SMA 5014.03 (-23.7%)
SMA 2009.809 (+9.2%)
Beta-0.03
S&P 52W Chg16.45%
Avg Vol (30d)1.60M
Avg Vol (10d)1.36M
Technical Indicators
RSI (14)30.4
MACD-0.9788
MACD Signal-0.7403
MACD Hist.-0.2385
BB Upper16.19 USD
BB Middle12.79 USD
BB Lower9.380 USD
BB Width53.29%
ATR (14)0.8643 USD
Vol Ratio (20d)0.50x